Abstract:Backgroud: Antithrombotic therapy is the cornerstone of chronic coronary syndrome (CCS) management. However, the best treatment option that optimally balances bleeding risk and efficacy remains undefined. Our objective was to evaluate the effectiveness and safety of antithrombotic options and identify the optimal treatment option for patients with CCS. Methods: We used the MEDLINE, CENTRAL and Embase databases to search for randomized controlled trials with follow-up periods longer than 12 months that compared aspirin (ASA) monotherapy with other antithrombotic therapies in patients with CCS. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used. Extracted data [hazard ratios (HR)] were pooled using Bayesian fixed-effect models, allowing the estimation of credible intervals (CrI) and posterior probabilities of benefit, harm, and practical equivalence. Confidence in the results was assessed with the Confidence In Network Meta-Analysis (CINeMA) tool. The primary efficacy and safety outcomes were major adverse cardiovascular events (MACE) and primary bleeding, respectively. Secondary outcomes were acute myocardial infarction, ischemic stroke, all-cause, and cardiovascular-specific mortality. Results: Five trials with a total of 80,605 patients were included. Mean patient age ranged from 61 to 69 years, while 20.3% to 31.4% were women. The reference treatment was ASA monotherapy. ASA + prasugrel 10 mg and clopidogrel 75 mg monotherapy presented the greatest benefit for MACE [HR 0.52 (95% CrI, 0.39–0.71); and 0.68 (95% CrI, 0.54–0.88)]. There was a probability of 98.8% that ASA + ticagrelor was practically equivalent to ASA monotherapy. Regarding the primary bleeding outcome, clopidogrel 75 mg monotherapy performed best [HR 0.64 (0.42, 0.99)]. There was a probability of 97.4% that ASA + Prasugrel 10 mg increases bleeding (HR > 1.0). Secondary outcome results followed a similar treatment ranking pattern as in primary outcomes. Overall, CINeMA confidence ratings were judged as either low or very low. Conclusions: These results revealed that clopidogrel monotherapy might provide the best risk-benefit balance in treating CCS. However, low CINeMA confidence ratings may preclude more forceful conclusions. Our analysis suggests that current guidelines recommending ASA as first-line therapy for CCS management need to be revised to include additional pharmacological options.

Antithrombotic treatment for chronic coronary syndrome: Evidence and future perspectives

Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects

Antithrombotic Therapy in Patients with Chronic Coronary Syndromes

Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

Individualising Antithrombotic Strategies for Acute and Chronic Coronary Syndromes

Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Controversy in cardiology: clopidogrel or acetylsalicylic acid in the treatment of chronic coronary syndromes?

Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review

Antithrombotic regimens for the prevention of major adverse cardiac events in chronic coronary syndrome: A systematic review and network meta-analysis

Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement

[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?]

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

[Long-term management of post acute coronary syndrome with oral antiplatelet therapy]

Antithrombotic Therapy Following Structural Heart Disease Interventions: Current Status and Future Directions

Coronary artery bypass grafting in acute coronary syndromes: modern indications and approaches

Current Management of Non-ST-Segment Elevation Acute Coronary Syndrome

Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease

Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease